- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05689931
Blodleukocytprofilering vid eosinofil typ 2-astma: Inverkan av systemisk IL-5-inriktning
The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.
The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Skåne County
-
Lund, Skåne County, Sverige, 22185
- The Lung and Allergy Clinic, Skåne University Hospital (SUS)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.
Beskrivning
Inclusion Criteria:
- Clinical diagnosis of asthma (the asthma patient arms)
- Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)
Exclusion criteria:
- Any diagnosed infection (all arms)
- Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: CROSS_SECTIONAL
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Asthma patients initiating Mepolizumab treatment
Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Andra namn:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Andra namn:
|
|
Asthma patients already on Mepolizumab treatment
Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Andra namn:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Andra namn:
|
|
Asthma patients without Mepolizumab treatment
Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections |
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Andra namn:
|
|
Healthy non-asthmatic control subjects
Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Blood Eosinophil Marker Expression
Tidsram: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Basophil Marker Expression
Tidsram: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Leukocyte Composition
Tidsram: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Blood T Lymphocyte Marker Expression
Tidsram: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio). |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood B Lymphocyte Marker Expression
Tidsram: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Leukocyte Total Cell Counts
Tidsram: Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
Routine clinical laboratory total leukocyte counts in peripheral blood |
Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Forced Expiratory Volume in 1 Second (FEV1)
Tidsram: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Expiratory Volume, 1s; (FEV1). |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Forced Vital Capacity (FVC)
Tidsram: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Vital Capacity (FVC) |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Exhaled FeNo
Tidsram: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
Fractional exhaled NO will be measured at multiple flows |
Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Jonas Erjefält, Lund University Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1072615
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .